Drugmakers can't be excited about the wave of consolidation going through the health insurance business. After all, pharma knows firsthand how mergers can put the screws to prices; just think of Express Scripts and its Medco buyout.
Last week, analysts pointed out that Horizon Pharma had plenty of potential buyouts to choose from, unlike bigger companies looking for bigger deals. Now, the $5 billion market-cap company has zeroed in on a target: Depomed, the pain drug specialist.
Last month, Mylan Chairman Robert Coury challenged suitor Teva to either put up a formal bid or step aside and let his company proceed with its plan to pursue its own target, Perrigo. And he may be getting what he asked for.
As the market for psoriasis meds heats up, companies are throwing down some hefty chunks of change to snag airtime for their TV spots.
Greeks rejected their proposed bailout over the weekend, but so far drugmakers say they're continuing to ship products to the country. Greek hospitals already owe pharma more than $1 billion, and the lack of a fiscal deal means the bills will keep stacking up. Bank closures could complicate other payments.
The Busches, the Mellons, the Rockefellers--they're some of America's richest families. But one blockbuster pain drug has put a family of pharma-founders ahead of them all in the wealth department.
With the second quarter now past, number-crunchers are trying to anticipate the next round of pharma earnings. And for Johnson & Johnson, the word is that its fast-growing drugs will keep on delivering year-over-year growth--with one key exception.
Drugmakers are ready to pounce on Japan's rapidly growing pharmaceutical market, and Sanofi and Gilead are hopping on the bandwagon with a fresh crop of approvals. Sanofi got a regulatory OK for diabetes newcomer Toujeo, while Gilead got a greenlight for hep C combo med Harvoni in the country.
Hospira continues to forge a new market reality around biosimilars, capturing wide swathes of market share with deep discounts for its biosimilar of Merck's arthritis blockbuster Remicade. Hospira has reportedly captured a public contract in France by offering a price that amounts to a 45% savings.
What's with all the M&A rumors floating around in the animal health world? Just look at Zoetis' Apoquel and it's clear why Big Pharma names are keen to bolster their positions in the space.
Out with the old guard, in with the new. In another sign that Big Biotech is elbowing into the top levels of pharma, Celgene has agreed to buy Merck & Co.'s old campus in Summit, NJ, adding the sprawling 1.3-million-square-foot complex to its already growing operations in the city.
When Boehringer Ingelheim's COPD drug Stiolto Respimat won U.S. approval early last month, the company's head of pharma marketing and sales, Allan Hillgrove, acknowledged that payer arm-twisting happening stateside may make pricing tough. But now, the German drugmaker has nabbed some European approvals that should give the drug a lift.
A team of Stanford University scientists think they have found a potential reason why GlaxoSmithKline's now-withdrawn flu shot Pandemrix was associated with a spike in narcolepsy cases.
Eye blockbuster Eylea has been churning out serious revenue growth for Regeneron since it hit the market, and now the company is inching closer to approval for its much-watched PCSK9 therapy. But what comes after that for the New York biotech? Analysts disagree.
We've heard plenty of anecdotal reports about expensive drugs, from the long-running brouhaha over Gilead Sciences' hepatitis C drugs to the consternation about pricey new cancer meds. But occasionally, there's a broader view--and not surprisingly, that shows some impressive price inflation, too.
Bayer and Johnson & Johnson know that right now, there's an impression out there that rival drug Eliquis--from Pfizer and Bristol-Myers Squibb--is superior to their next-gen clot-fighter Xarelto, despite their drug's market-share lead.
The FDA has issued AstraZeneca's least favorite form of draft guidance--the kind that helps other drugmakers develop copies of a blockbuster seller.
Germany's tough price negotiators went too far for Novo Nordisk. The Danish drugmaker is pulling its new diabetes drug Tresiba off the market after authorities said they'd price the long-acting basal insulin on par with old human insulin injections.
Biogen has looked at its pipeline of promising drug candidates for things like Alzheimer's disease and multiple sclerosis, measured that against its manufacturing network and decided it is going to need more capacity. The company announced on Tuesday that it will start with a $1 billion plant in Switzerland, where it expects to add 400 jobs.
In 2013, GlaxoSmithKline CEO Andrew Witty pledged to end doctor payments by 2016 as part of an effort to clean up the company's image. But so far, little has changed in that department.